Day 5. Tuesday 31st May
Theme 5. AI, Intellectual Property, Patentability
10.00. PETER HARRISON, Law School, University of York
DNA Patentability
Peter Harrison (Law School) the University of York, UK. Following a PhD in Pharmacology for work on mechanisms of brain cell death in hypoxia, an EU post-doctoral fellowship in molecular biology at the CNRS, Gif-sur-Yvette, Paris, and qualification as a lawyer, he practiced law for 20 years with a particular interest in enforcing and exploiting intellectual property rights in the pharmaceuticals, biotechnology and chemicals sectors. He has litigated in high-profile patent cases in the English High Court and Court of Appeal, Trial and Appeal Divisions of the Federal Court of Canada, the Court of Justice of the European Union and the European Patent Office. Peter’s research focus is on the interface between intellectual property rights and biological innovation. On his return to academia, he received a PhD in Law for his work on the protection of indigenous peoples’ right to control genetic resources and related traditional knowledge
11.00. SVEN J.R. BOSTYN, University of Copenhagen
IP Law in an Age of Pandemics
Sven J.R. Bostyn (LLB, Lic. Jur., LLM, PhD) is Associate Professor of Biomedical Innovation Law at the Centre for Advanced Studies in Biomedical Innovation Law (CeBIL http://cebil.dk ), Faculty of Law, University of Copenhagen, an Assistant Professor of Intellectual Property Law at the Institute for Information Law (IVIR) of the University of Amsterdam, Visiting Professor at the University of Turin (Italy) and Tongji University (Shanghai), and consultant in IP. He is also a regular guest professor at CEIPI in Strasbourg. He is a world authority in the area of patent law relating to pharmaceuticals, biotechnology, medical devices, software and SPC’s, and also a world authority in the area of plant patents and plant variety rights. He is also an expert in regulatory exclusivities (data and market exclusivity) in the area of pharmaceuticals in general, and orphan drugs and antibiotics in particular, and in trade secret law. He was between 2013 and 2016 the Chair of the Expert Committee at the European Commission on the development and implications of patent law in the field of biotechnology and genetic engineering, after having been a member of and Rapporteur at an earlier European Commission Expert Group (2003-2006). Besides the European Commission, he has also advised both the Belgian and Dutch governments on policy matters regarding patentability of biotechnological and software inventions. He is often consulted as an expert in patent law, regulatory exclusivities and licensing matters, by government institutions and by practitioners in the framework of litigation. Sven is the author of more than 70 single authored scientific peer reviewed publications, amongst which two widely acclaimed monographs.
12.00. Francesco Banterle, Hoganlovells,
Ownership of Inventions Created by Artificial Intelligence
Francesco Banterle is an IP lawyer specialised in copyright and patent laws. Francesco holds a PHD in IP law and he is lecturer at the University of Milan where he teaches Managing and Evaluating Intellectual Property Rights. He is senior associate at Hogan Lovells where he focuses on multi-jurisdictional patent and copyright litigation
13.00. GIORGIO REMOTTI, Dipartimento di Scienze Economiche e Aziendali, Pavia,
Few Remarks on the Ownership of Inventions made by AI
Giorgio Remotti is a post-doc researcher in Commercial and European Union Law at the University of Eastern Piedmont. He holds a Ph.D. in IP Law at the University of Pavia. He collaborates with various research centers and is a member of the editorial board of some scientific journals. Giorgio is a lecturer at the University of Pavia, where he teaches Competition Law. At the University of Urbino, he teaches International Trade Law in the Ph.D. school in Global Studies”.
13.15. Roundtable: Technology, Medicine and Patentability
15.00. Student’s Participation
15.30.-17.00. PBL Scenario 2 (Conclusions: Discussing Learning Outcomes)